ERBB2 and breast cancer: The National Comprehensive Cancer Network (NCCN) guidelines recommend neoadjuvant therapy (NACT) as an effective strategy for high‐risk breast cancer subtypes (e.g., triple‐negative or HER2‐positive) [7].